Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2021 Jan 26.
Published in final edited form as: Toxicol Pathol. 2019 May 7;47(5):577–584. doi: 10.1177/0192623319845838

Do GISTs Occur in Rats and Mice? Immunohistochemical Characterization of Gastrointestinal Tumors diagnosed as Smooth Muscle Tumors in The National Toxicology Program

Kyathanahalli S Janardhan 1, Priyanka Venkannagari 2,3, Heather Jensen 2, Mark J Hoenerhoff 2,4, Ronald A Herbert 2, David E Malarkey 2, Robert C Sills 2, Arun R Pandiri 2
PMCID: PMC7836069  NIHMSID: NIHMS1526479  PMID: 31064278

Abstract

The majority of the tumors in the gastrointestinal (GI) tract of rats and mice, with spindle cell morphology, are diagnosed as smooth muscle tumors (SMTs). Similarly, several decades ago human gastrointestinal tumors with spindle cell morphology were also diagnosed as SMTs. However, later investigations identified most of these tumors in humans as gastrointestinal stromal tumors (GISTs). The GISTs are considered to arise from the interstitial cells of Cajal located throughout the GI tract. Positive immunohistochemical staining with CKIT antibody is a well-accepted diagnostic marker for GISTs in humans. Since there is a considerable overlap between the histomorphology of SMTs and GISTs, it is not possible to distinguish them on hematoxylin and eosin stained sections. As a result, GISTs are not routinely diagnosed in toxicological studies. The current study was designed to evaluate the tumors diagnosed as leiomyoma or leiomyosarcoma in the National Toxicology Program’s two-year bioassays using CKIT, smooth muscle actin and desmin immunohistochemistry. The results demonstrate that most of the mouse SMTs diagnosed as leiomyoma or leiomyosarcoma are likely GISTs, whereas in rats the tumors are likely smooth muscle tumors and not GISTs.

Keywords: GIST, CKIT, smooth muscle actin, desmin, leiomyoma, leiomyosarcoma, mesenchymal tumors, smooth muscle tumors, Immunohistochemistry, Gastrointestinal stromal tumor

Introduction

In toxicological studies, the majority of the tumors in the gastrointestinal (GI) tract of rats and mice with a spindle cell morphology are diagnosed as leiomyoma or leiomyosarcoma1. In the 1930s, human gastrointestinal tumors with spindle cell morphology were also diagnosed as leiomyoma and leiomyosarcoma 2-4 The diagnosis was not challenged until some of the ultrastructural observations questioned the accuracy of the leiomyoma/leiomyosarcoma diagnosis 3-6. Later, certain immunohistochemical observations further strengthened the doubts on smooth muscle cell origin of these tumors. With these developments, the term “stromal tumor” was introduced in 1983 for human tumors 4,5 The diagnosis of Gastrointestinal Stromal Tumors (GISTs) gained more importance after the demonstration of gain of function mutation in the CKIT gene in mesenchymal tumors of the human GI tract 7 Now, it is accepted that GISTs arise from the interstitial cells of Cajal (ICC), pacemaker cells in the intestinal wall, and CKIT, a protooncogene, has been recognized as a reliable marker of GISTs 8,9. Based on the CKIT positivity, the majority of human GI tumors with spindle cell morphology are now classified as GISTs and not leiomyoma or leiomyosarcoma.

Histologically, GISTs have a spindle cell morphology, similar to smooth muscle tumors and hence it is difficult to distinguish between the two lesions based on hematoxylin and eosin (H&E) stained sections. In humans, clinical behavior of GISTs is variable and therefore, they are categorized for risk of malignant behavior based on the size and mitotic index. Although accurate incidence rate for the human GIST in the USA is not available (Gastrointestinal Stromal Tumors Treatment (PDQ®)-Health Professional Version, the National Cancer Institute https://www.cancer.gov/types/soft-tissuesarcoma/hp/gist-treatment-pdq#cit/section_1.3 ; accessed on 0111 2019) it is estimated to be ~6.8 cases/million/year 10. In chronic rat and mouse toxicity/carcinogenicity bioassays conducted by the National Toxicology Program (NTP), GIST is not routinely diagnosed. In addition, no treatment-related mesenchymal gastrointestinal tumors have been reported in the NTP’s rat and mouse toxicity/carcinogenicity bioassays. Knowledge of GIST’s existence in rats and mice will help in understanding the relevance of rodent GI tumors with spindle cell histomorphology to human health, especially if the tumors are treatment-induced. Our current study was designed to address this data gap by evaluation of rat and mouse GI tumors diagnosed as leiomyomas or leiomyosarcomas in the NTP’s toxicity/carcinogenicity bioassays.

Materials and Methods

The NTP’s two-year toxicity/carcinogenicity bioassay database (from 1982-2013) was searched for the diagnosis of leiomyoma and leiomyosarcoma in the stomach, duodenum, jejunum, ileum, cecum, colon and rectum of rats and mice. Routinely, in the NTP bioassays, tissues are fixed in formalin for up to six months. Formalin-fixed paraffin-embedded (FFPE) blocks (rats, n=54; mice, n=32) were retrieved from the NTP archives. The sample selection was based on the availability of the FFPE blocks, ability to obtain sufficient sections from the block and the extent of tissue autolysis/necrosis. Five-micron-thick sections were collected on charged slides. One slide from each block was stained with hematoxylin and eosin stain, and the rest of the slides were used for immunohistochemistry.

The tissue sections were deparaffinized in xylene and rehydrated through decreasing grades of alcohol followed by Tris Buffered Saline automation wash buffer (Biocare Medical, CA). Endogenous peroxidase was quenched by incubating the tissue sections with 3% hydrogen peroxide. Endogenous biotin and non-specific binding of avidin/biotin were blocked using an avidin-biotin blocking kit (Vector Laboratories, CA) after which the sections were incubated with the primary antibody (Table 1). For the negative controls, tissue sections were incubated with either normal rabbit serum or normal rabbit IgG. The concentration of the negative control serum was normalized to that of primary antibody. Subsequently, the sections were incubated with a secondary antibody (Table 1) followed by Vectastain Elite ABC kit (Vector Laboratories, CA) or Rabbit on Rodent HRP (Biocare Medical, CA) for 30 min. The antigen-antibody complex was visualized using 3,3'-diaminobenzidine (DAB) chromogen. Finally, the slides were counterstained with hematoxylin, dehydrated through increasing grades of alcohol, cleared in xylene and coverslipped.

Table 1:

Details of immunohistochemistry

Antibody Desmin Smooth muscle actin CKIT (CD117)
Primary antibody source Abcam, MA Abcam, MA Dako, CA
Catalog number Ab15200 Ab5694 A4502
Lot number GR65813-2 GR110346-1 (mouse); GR34424-1 (rat) 10089553 (mouse); 10063182 (rat)
Concentration 0.2 mg/ml 0.2 mg/ml0.2 mg/ml 12.5 mg/ml; 10.6 mg/ml
Dilution 1:300 1:1000 (mouse) 1: 750 (rat) 1:500
Incubation time 1 hour1 hour 1 hour 30 minutes
1 hour
Negative control Normal Rabbit IgG Normal Rabbit IgG Normal rabbit serum
Catalog number NI01 NI01 011-000-001
Source Calbiochem Calbiochem Jackson Immunoresearch
Positive controls used Mouse GI tract tissues Mouse GI tract tissues Mouse and rat GI tract tissues
Rat heart Rat uterus
Antigen retrieval Distilled water/Microwave (mouse) None EDTA pH 8.4 in Decloaker
Citrate buffer pH 6.0 in Decloaker (rat)
Secondary antibody Donkey anti-rabbit antibody Goat anti-rabbit antibody Rabbit on Rodent HRP-Polymer
Source and catalog number Jackson 711-065-152 Vector BA-1000 Biocare RMR622
Lot number 133272;103296 Y0515; X0524 010214; 021212
Concentration 1.5 mg/ml; 1.6 mg/ml 1.5 mg/ml N/A
Dilution 1:500 1:500 Ready to use
Incubation time 30 minutes 30 minutes 30 minutes
Additional reagents VECTASTAIN Elite ABC HRP VECTASTAIN Elite ABC HRP N/A
Source and catalog number Vector PK-7200 Vector PK-7200
Dilution Ready to use Ready to use
Incubation time 30 minutes 30 minutes
Chromogen DAB DAB DAB

Results:

The combined incidence of leiomyoma and leiomyosarcoma of the gastrointestinal tract in F344 rats from 203 two-year toxicity/carcinogenicity bioassays of NTP was determined using the data available in the NTP database. The combined incidence was 118/42,037 (0.28%) in males, and 67/39,629 (0.16%) in females. The tumors were present in stomach, duodenum, jejunum, ileum, cecum, colon and rectum. The majority of tumors were present in stomach and jejunum in males, and in jejunum and duodenum in females. The distribution of tumors in various tissues is shown in Figure 1.

Figure 1:

Figure 1:

Incidence of leiomyoma/leiomyosarcoma in rats in the National Toxicology Program’s 2-year bioassays. The graphs represent the total incidences of leiomyoma/leiomyosarcoma found in 42,037 males and 39,629 females across 203 two-year toxicity/carcinogenicity bioassays.

The combined incidence of leiomyoma/leiomyosarcoma in B6C3F1/N mice was determined from 195 two-year NTP bioassays. The combined incidence was 25/40,226 (0.06%) in males, and 106/40,229 (0.26%) in females. The majority of tumors were present in cecum in both males and females. Distribution of tumors in various tissues is shown in Figure 2.

Figure 2:

Figure 2:

Incidence of leiomyoma/leiomyosarcoma in the mice in the National Toxicology Program’s 2-year bioassays. The graphs represent the total incidences leiomyoma/leiomyosarcoma found in 40,226 males and 40,229 females across 195 two-year toxicity/carcinogenicity bioassays.

Histologically, the majority of rat tumors involved tunica muscularis externa and interna. In some instances, tumors also occupied the submucosa. Approximately 50% of the tumors were well circumscribed. Mitotic figures were rare except for 25% of the cases, which had frequent mitotic figures (~ 1-3/40x field). In 85% of the cases, the neoplasm was composed of interlacing bundles or whorls of spindle-shaped cells and in the remaining cases the neoplasm was composed of closely packed round to oval cells. One tumor had an epithelioid morphology admixed with spindle cells. Inflammatory cell infiltration was a common feature; eosinophilic-, lymphocytic- and mast cell infiltrations were present in 85%, 15% and 20% of the cases, respectively. In a small number of cases inflammatory cell infiltration was not a feature. A moderate amount of collagen was present between the neoplastic cells in 40% of the cases.

Similar to rats, the majority of the tumors in mice involved both tunica muscularis interna and externa. Approximately 63% of the tumors were well circumscribed. Mitotic figures were occasional to rare in approximately 53% of the cases while the rest had frequent mitotic figures (~ 1-3/40x field). In 83% of the cases, the neoplasm was composed of interlacing bundles or whorls of spindle-shaped cells. In the rest of the cases (4/32) the neoplasm was composed of closely packed epithelioid or a mix of epithelioid and spindle cells. Unlike tumors of the rat, inflammatory cell infiltration was not a feature in mouse GI spindle cell tumors. Two of the tumors were very different from the rest in having a large amount of collagen.

Since CKIT IHC was used to distinguish the GIST from smooth muscle tumors, normal intestine was stained to demonstrate the specificity of the antibody. In both rat and mouse intestine, the positively stained cells located within the tunica muscularis were consistent with the phenotype of the ICCs and the CKIT antibody did not stain the smooth muscle cells (Figure 3).

Figure 3:

Figure 3:

Demonstration of CKIT staining in normal colon of a rat (A) and normal duodenum of a mouse (B). The cells staining positive (arrows) are present between the muscle layers and in submucosa, locations consistent with the presence of interstitial cells of Cajal. There is no staining in the smooth muscle cells (asterisks). 3,3'-diaminobenzidine (DAB) chromogen and hematoxylin counterstain.

Immunohistochemically, 54/54 rat tumors were negative for CKIT, 53/54 were positive for desmin and 45/54 were positive for smooth muscle actin (SMA). The one tumor that was negative for desmin was positive for smooth muscle actin. Staining for SMA was weak and was present in a small percentage of neoplastic cells (<10%) as opposed to staining for desmin in almost all of the neoplastic cells. Both the desmin and SMA staining was cytoplasmic. Based on the IHC pattern, all the tumors in rats were likely smooth muscle tumors and not GISTs (Figure 4).

Figure 4:

Figure 4:

Smooth muscle tumor in the stomach of a rat. Hematoxylin and eosin stained section (A&E) shows the tumor (asterisk) involving tunica muscularis and submucosa. Spindle-shaped neoplastic cells are forming interlacing bundles. Many mitotic figures are present (arrows). The tumor is negative for CKIT (B and F), shows intense staining for desmin (C and G) and weaker staining for smooth muscle actin (D and H). Very pale brown staining seen in (F) was considered to be non-specific staining based on the negative control slide. The smooth muscle actin staining is present in smaller percentage of cells and is not appreciable in D. However, in D, positive staining in tunica muscularis (arrows; internal control) can be appreciated. 3,3'-diaminobenzidine (DAB) chromogen and hematoxylin counterstain.

In mice, 22/32 (69%) tumors were positive for CKIT and hence are probably GISTs (Figure 5). The staining for CKIT was cytoplasmic and was present in almost all the neoplastic cells in 19 of the 22 tumors. In the other three CKIT-positive tumors, the staining was present in 70%, 30% and 15% of the neoplastic cells. Of these 22 CKIT-positive tumors, three also had desmin positivity and the rest were negative for desmin. In these tumors, desmin positivity was cytoplasmic and observed only in a very small percentage of neoplastic cells (<10%). All the CKIT-positive tumors were negative for SMA. Out of the 22 CKIT-positive tumors, 16 were in cecum, 5 were in colon and one was in stomach. Five of the 32 tumors (16%) were positive for either desmin and/or SMA and therefore considered to be smooth muscle tumors (SMTs). Staining for SMA was cytoplasmic, when present. Five of the 32 tumors were negative for all the three markers. Out of these five tumors, four were in small intestine (duodenum/jejunum) and one was in the cecum.

Figure 5:

Figure 5:

Tumor in the cecum of a mouse. Hematoxylin and eosin stained section (A and E) shows the tumor (asterisk) involving submucosa and part of tunica muscularis. The tumor is composed of bundles of spindle-shaped cells. The tumor shows staining for CKIT (B and F) and no staining for desmin (C and G) and smooth muscle actin (D and H). Smooth muscle, internal negative controls for CKIT, in B (arrow) and F (asterisk) had no staining. Smooth muscle, internal positive control for desmin and smooth muscle actin (arrow in C and D; asterisk in G and H) showed staining. 3,3'-diaminobenzidine (DAB) chromogen and hematoxylin counterstain.

Discussion:

Histologically, leiomyomas in the gastrointestinal tract are characterized by the presence of interlacing bundles or whorls of spindle-shaped cells with cigar-shaped or blunt ended nuclei. In addition to the features described above, leiomyosarcomas also have pleomorphic cells, increased mitotic activity and can commonly have necrosis, cystic change and mineralization 11. Gastrointestinal stromal tumors have been reported in humans and dogs 12,13. In rats and mice, spontaneous GISTs are very rare, and can be experimentally induced in rats by duodenal reflux, and in mice by Ckit mutations 14-17 Histologically, GISTs are characterized by the presence of interlacing bundles or whorls of spindle-shaped cells. Because of this histological resemblance to smooth muscle tumors, it is often difficult to distinguish GISTs from leiomyomas/leiomyosarcomas based on H&E stained sections alone, and immunohistochemistry is essential to diagnose GISTs 11. In the current study, the histological features of GISTs were similar to what has been described for leiomyomas/leiomyosarcomas.

Human GISTs have been shown to harbor mutations in the CKIT gene, and the neoplastic cells consistently stain with CKIT antibody 7. In the current study, a commercially available rabbit polyclonal antibody was used. The antibody was first tested to determine if it specifically identifies ICC in normal tissues. Interstitial cells of Cajal are located in the submucosa, between and within the circular and longitudinal muscle layer of tunica muscularis, around myenteric plexus and submucosal plexus 18. In the normal mouse and rat GI tract tissues tested, the antibody proved to be specific as it stained only the cells that matched the location of ICC and did not stain any smooth muscle or epithelial cells. None of the rat tumors stained with CKIT antibody, but stained with SMA and desmin antibodies, indicating that the rat tumors are likely SMTs and not GISTs. Although the rat tumors are very likely to be SMTs, possibility of other tumors of myoid lineage such as rhabdomyosarcoma and inflammatory myofibroblastic tumors of cannot be completely ruled-out. In contrast to the rat tumors, the majority of mouse tumors did stain with CKIT and not with SMA or desmin, indicating that many of the mouse tumors diagnosed as leiomyoma or leiomyosarcomas are probably GISTs. In humans, the majority of GISTs occur in stomach (60%) and in small intestine (25%)4. The majority of CKIT-positive tumors of mouse in the current study occurred in cecum. Use of only immunohistochemistry as a tool to evaluate the tumors is a limitation of this manuscript. Ideally, immunohistochemical findings should be supported by other assays such as western blots, in situ hybridization, RT-PCR and electron microscopy 19. However, suitable samples were not available for any of these analyses. Because of the rarity of these tumors and this being a retrospective study, the only available material was formalin-fixed paraffin-embedded (FFPE) tissue blocks that could be used for immunohistochemistry. Prolonged fixation (up to 6 months) affected the nucleic acid quality and therefore, in situ hybridization or RT-PCR could not be performed. Prolonged fixation in formalin is not amenable for ultrastructural examination as it yields poor morphology and definitive conclusions cannot be made. However, immunohistochemical demonstration of CKIT in the tumors is considered to be diagnostic of GISTs 11,20,21, and in humans, CKIT immunohistochemistry is approved by FDA for diagnostic purposes (https://www.accessdata.fda.gov/cdrhdocs/pdf4/P040011A.pdf; accessed on January 21, 2019). Therefore, it can be concluded that the majority of mouse gastrointestinal tumors are probably GISTs. In three of the CKIT-positive tumors, there was also staining for desmin in a small percentage of neoplastic cells. In humans, a small percentage of CKIT-positive tumors can stain with desmin 21. Five of the tumors were negative for any of the IHC markers used in this study and the internal controls stained as expected in these samples. A small percentage of human tumors have been reported to be negative for CKIT4 and it is possible that the tumors are CKIT-negative GISTs. In humans, other markers such as CD34 can also be used to diagnose GISTs12. The histomorphology of the tumors that did not stain with the three markers was similar to the tumors that did express the three markers evaluated. This suggests that the triple negative tumors may not be poorly differentiated tumors. Although the CKIT-positive tumors in mice are probably GISTs, other tumors such as mast cell tumor and melanoma with spindle cell morphology can also express CKIT and can’t be completely ruled-out.

As early as 1889, Cajal, using Golgi-stained intestinal tissue of rat and rabbit, described the histological features of ICCs, from which GISTs arise 4,7,22. Current knowledge on the distribution and morphology proven by various techniques is very much similar to what was described by Cajal more than a century ago 22-24 Both ICCs and GISTs express CKIT receptor 12,25,26. Binding of the KIT ligand (stem cell factor) activates KIT receptor and helps in normal functioning of ICCs which are pacemaker cells of the GI tract 27-29. On the other hand, activating mutations in the Ckit oncogene can cause proliferation of ICCs leading to GISTs 7,12,14. In humans, 75-80% of GISTs have CKIT mutations on one of the exons 11, 9, 13 and 17 with the majority involving exon 11 4,9 Similar mutations on exon 11 in canine GISTs have been reported 13,30. Limited sample size and prolonged fixation (up to 6 months) of tissues in the current project did not allow evaluation for mutations. Such evaluations, when possible, will help in understanding the molecular pathogenesis of GISTs in mice.

The majority of mouse tumors in NTP studies that were previously diagnosed as SMTs are probably GISTs. However, the incidences of these SMTs in the GI tract were sporadic and never occurred as a treatment related finding in any of the NTP rat and mouse toxicity/carcinogenicity bioassays. Thus, the current finding will not affect the outcomes of previous NTP bioassays. In the future, any tumor in the GI tract with spindle cell morphology should be considered for immunohistochemical evaluation using SMA, desmin and CKIT antibodies. This is essential especially when a treatment related increase in GI tract tumors with spindle cell morphology is observed. This will also enable building a meaningful historical control database for GISTs and will allow us to determine the translational relevance of the treatment related increase in GISTs. To conclude, it appears that the majority of GI tumors with spindle cell morphology diagnosed as SMTs in mice are probably GISTs. There is no evidence for the occurrence of GISTs in rats based on CKIT, desmin and SMA immunohistochemistry. Immunohistochemical evaluation of any tumor resembling SMT in the GI tract of a mouse is essential for appropriate diagnosis of tumors. The conclusions are based on the evaluation of SMTs. Additional studies are required to verify if the conclusions of this study hold true for other GI tract tumors with spindle-cell morphology such as schwannomas.

Acknowledgements

The authors thank the DNTP/NIEHS Pathology Support Group, histology and immunohistochemistry core laboratories for their technical assistance. We also thank Chemical Effects in Biological Systems (CEBS) database team at DNTP for their help with searching the NTP study database, Drs. Mark Cesta and Daven Jackson-Humbles for the critical review of the manuscript, and the staff of the NTP Archives at EPL, Inc., for their assistance in retrieving the samples.

Footnotes

Declaration of Conflicting of Interest Statement

Author(s) declared no potential, real, or perceived conflicts of interest with respect to the research, authorship, and/or publication of this article.

References:

  • 1.Nakatsuji S, Szabo KA, Elmore SA. Chapter 7 - Small and Large Intestine A2 - Suttie Andrew W. In: Boorman's Pathology of the Rat (Second Edition). Boston: Academic Press; 2018:51–69. [Google Scholar]
  • 2.Starr GF, Dockerty MB. Leiomyomas and leiomyosarcomas of the small intestine. Cancer. 1955;8(1):101–111. [DOI] [PubMed] [Google Scholar]
  • 3.Franquemont DW. Differentiation and Risk Assessment of Gastrointestinal Stromal Tumors. American Journal of Clinical Pathology. 1995;103(1):41–47. [DOI] [PubMed] [Google Scholar]
  • 4.Corless CL, Fletcher JA, Heinrich MC. Biology of Gastrointestinal Stromal Tumors. Journal of Clinical Oncology. 2004;22(18):3813–3825. [DOI] [PubMed] [Google Scholar]
  • 5.Mazur MT, Clark HB. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol. 1983;7(6):507–519. [DOI] [PubMed] [Google Scholar]
  • 6.Welsh RA, Meyer AT. Ultrastructure of gastric leiomyoma. Archives of pathology. 1969;87(1):71–81. [PubMed] [Google Scholar]
  • 7.Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279(5350):577–580. [DOI] [PubMed] [Google Scholar]
  • 8.Corless CL. Gastrointestinal stromal tumors: what do we know now? Modern Pathology. 2014;27:S1. [DOI] [PubMed] [Google Scholar]
  • 9.Oppelt PJ, Hirbe AC, Van Tine BA. Gastrointestinal stromal tumors (GISTs): point mutations matter in management, a review. Journal of gastrointestinal oncology. 2017;8(3):466–473. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Tran T, Davila JA, El-Serag HB. The Epidemiology of Malignant Gastrointestinal Stromal Tumors: An Analysis of 1,458 Cases from 1992 to 2000. The American Journal Of Gastroenterology. 2005;100:162. [DOI] [PubMed] [Google Scholar]
  • 11.Nolte T, Brander-Weber P, Dangler C, et al. Nonproliferative and Proliferative Lesions of the Gastrointestinal Tract, Pancreas and Salivary Glands of the Rat and Mouse. J Toxicol Pathol. 2016;29(1 Suppl):1S–125S. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Miettinen M, Lasota J. Gastrointestinal stromal tumors – definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Archiv. 2001;438(1):1–12. [DOI] [PubMed] [Google Scholar]
  • 13.Frost D, Lasota J, Miettinen M. Gastrointestinal Stromal Tumors and Leiomyomas in the Dog: A Histopathologic, Immunohistochemical, and Molecular Genetic Study of 50 Cases. Veterinary Pathology. 2003;40(1):42–54. [DOI] [PubMed] [Google Scholar]
  • 14.Sommer G, Agosti V, Ehlers I, et al. Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase. Proceedings of the National Academy of Sciences. 2003;100(11):6706–6711. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Rubin BP, Antonescu CR, Scott-Browne JP, et al. A Knock-In Mouse Model of Gastrointestinal Stromal Tumor Harboring Kit K641E. Cancer Research. 2005;65(15):6631–6639. [DOI] [PubMed] [Google Scholar]
  • 16.Fujimoto H, Shibutani M, Kuroiwa K, et al. A Case Report of a Spontaneous Gastrointestinal Stromal Tumor (GIST) Occurring in a F344 Rat. Toxicologic Pathology. 2006;34(2):164–167. [DOI] [PubMed] [Google Scholar]
  • 17.Mukaisho K-i, Miwa K, Totsuka Y, et al. Induction of gastric GIST in rat and establishment of GIST cell line. Cancer Letters. 2006;231(2):295–303. [DOI] [PubMed] [Google Scholar]
  • 18.Komuro T. Structure and organization of interstitial cells of Cajal in the gastrointestinal tract. The Journal of physiology. 2006;576(Pt 3):653–658. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Janardhan KS, Jensen H, Clayton NP, Herbert RA. Immunohistochemistry in Investigative and Toxicologic Pathology. Toxicol Pathol. 2018;46(5):488–510. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Nishida T, Blay JY, Hirota S, Kitagawa Y, Kang YK. The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines. Gastric Cancer. 2016;19(1):3–14. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Turner MS, Goldsmith JD. Best practices in diagnostic immunohistochemistry: spindle cell neoplasms of the gastrointestinal tract. Arch Pathol Lab Med. 2009;133(9):1370–1374. [DOI] [PubMed] [Google Scholar]
  • 22.Thuneberg L One hundred years of interstitial cells of Cajal. Microsc Res Tech. 1999;47(4):223–238. [DOI] [PubMed] [Google Scholar]
  • 23.Takaki M Gut Pacemaker Cells: the Interstitial Cells of Cajal (ICC). Journal of Smooth Muscle Research. 2003;39(5):137–161. [DOI] [PubMed] [Google Scholar]
  • 24.Komuro T. Comparative morphology of interstitial cells of Cajal: ultrastructural characterization. Microsc Res Tech. 1999;47(4):267–285. [DOI] [PubMed] [Google Scholar]
  • 25.Hulzinga JD, Thuneberg L, Klüppel M, Malysz J, Mikkelsen HB, Bernstein A. W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity. Nature. 1995;373:347. [DOI] [PubMed] [Google Scholar]
  • 26.Ward SM, Burns AJ, Torihashi S, Sanders KM. Mutation of the proto-oncogene c-kit blocks development of interstitial cells and electrical rhythmicity in murine intestine. 1994;480(1):91–97. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Zsebo KM, Wypych J, McNiece IK, et al. Identification, purification, and biological characterization of hematopoietic stem cell factor from buffalo rat liver-conditioned medium. Cell. 1990;63(1):195–201. [DOI] [PubMed] [Google Scholar]
  • 28.Zsebo KM, Williams DA, Geissler EN, et al. Stem cell factor is encoded at the SI locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell. 1990;63(1):213–224. [DOI] [PubMed] [Google Scholar]
  • 29.Maeda H, Yamagata A, Nishikawa S, et al. Requirement of c-kit for development of intestinal pacemaker system. 1992;116(2):369–375. [DOI] [PubMed] [Google Scholar]
  • 30.Gregory-Bryson E, Bartlett E, Kiupel M, Hayes S, Yuzbasiyan-Gurkan VJBC Canine and human gastrointestinal stromal tumors display similar mutations in c-KIT exon 11. 2010;10(1):559. [DOI] [PMC free article] [PubMed] [Google Scholar]

RESOURCES